PRESS RELEASE published on 04/11/2025 at 20:05, 11 months 14 days ago Publication Annual Report - Annual Shareholders' Meeting Oxurion NV releases its annual report for the financial year 2024 and convenes its Annual Shareholders' Meeting in Leuven, Belgium. Developing ophthalmic therapies for retinal disease Shareholders' Meeting Annual Report Ophthalmic Therapies Oxurion NV Retinal Disease
BRIEF published on 04/04/2025 at 14:05, 11 months 21 days ago Oxurion General Meeting Postponed General Meeting Biopharmaceuticals Report Ophthalmic Therapies Oxurion
PRESS RELEASE published on 04/04/2025 at 14:00, 11 months 21 days ago Postponement Annual Shareholders Meeting Oxurion NV postponed its Annual Shareholders Meeting to May 13, 2025, due to pending annual accounts. The biopharmaceutical company, focused on ophthalmic therapies, is based in Leuven, Belgium Biopharmaceutical Annual Shareholders Meeting Postponed Ophthalmic Therapies Oxurion NV
BRIEF published on 04/02/2025 at 18:05, 11 months 23 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Actions Transparency Atlas Special Opportunities Oxurion Biopharmacy
PRESS RELEASE published on 04/02/2025 at 18:00, 11 months 23 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV, a biopharmaceutical company, received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian legislation Transparency Notification Shareholding Threshold Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
BRIEF published on 03/27/2025 at 18:05, 11 months 29 days ago Oxurion receives adjusted transparency notification Transparency Notification Shareholding Oxurion Atlas Special Opportunities II Brussels Stock Exchange
PRESS RELEASE published on 03/27/2025 at 18:00, 11 months 29 days ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received an amended transparency notification from Atlas Special Opportunities II, LLC regarding the sale of voting securities. This press release replaces the one from March 18, 2025 Transparency Notification Euronext Brussels Oxurion NV Retinal Disease Therapies Atlas Special Opportunities II
BRIEF published on 03/24/2025 at 18:05, 1 year ago Oxurion Announces Capital Increase Following Convertible Bond Conversion Convertible Bonds Capital Increase Atlas Special Opportunities Ophthalmic Therapies Oxurion
PRESS RELEASE published on 03/24/2025 at 18:00, 1 year ago Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC converts bonds in Oxurion, resulting in EUR 150,000 capital increase. Oxurion focuses on developing therapeutics for vision care Capital Increase Therapeutics Vision Care Atlas Special Opportunities LLC Oxurion
BRIEF published on 03/18/2025 at 18:35, 1 year ago Oxurion Signs Letter of Intent for Acquisition of Biometrics-Focused CRO Regulatory Compliance Oxurion Acquisition Biometrics CRO Clinical Data Management ECRF Platform
Published on 03/26/2026 at 00:40, 2 hours 53 minutes ago Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 3 hours 3 minutes ago Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 8 hours 18 minutes ago Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 14 hours 3 minutes ago Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/25/2026 at 13:30, 14 hours 3 minutes ago Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification
Published on 03/26/2026 at 01:05, 2 hours 27 minutes ago Blokees Announces Upgrade Brand Mission at 2026 Global Partner Conference
Published on 03/25/2026 at 20:00, 7 hours 32 minutes ago Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Published on 03/25/2026 at 19:41, 7 hours 52 minutes ago EQS-Adhoc: STRATEC POSTS IMPAIRMENTS, REPORTS PRELIMINARY RESULTS FOR 2025, AND OFFERS GUIDANCE FOR 2026
Published on 03/25/2026 at 19:30, 8 hours 3 minutes ago AIXTRON to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 19:26, 8 hours 6 minutes ago EQS-Adhoc: AIXTRON SE to expand global footprint with new plant in Malaysia
Published on 03/25/2026 at 18:31, 9 hours 2 minutes ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 9 hours 48 minutes ago Combined General Meeting on May 05, 2026: publication of the notice of Meeting
